This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
For many people with pain or inflammation, healthcare providers often prescribe medications like diclofenac or naproxen. These drugs belong to a group called nonsteroidal anti-inflammatory drugs (NSAIDs). Diclofenac and naproxen may help reduce inflammation and relieve pain caused by conditions like arthritis, menstrual cramps, or migraines. While both medications can help people relieve pain and discomfort that interferes with daily activities, they may differ in various ways.
Half of every dollar spent on medicines goes to entities that don’t make medicine—like pharmacy benefit managers (PBMs) and insurers who are aggressively consolidating their control over health care and hospitals, clinics and for-profit pharmacies in the 340B markup program. As entities in the supply chain that don’t make medicine are increasingly using medicines to subsidize other parts of their business, patients and employers face increasing costs and barriers to accessing c
Sally Arif, PharmD, professor in the College of Pharmacy at Midwestern University, discusses how pharmacists can effectively communicate with diverse patients.
Private equity firms are acquiring facilities that care for people with intellectual or developmental disabilities at an alarming rate, according to a new report released Tuesday. The care industry for this population has been historically owned and operated by nonprofits and faith-based institutions. However, between 2013 and 2023, private equity firms made over 1,000 acquisitions of disability and elder care providers — a likely undercount, according to the report published by the Priva
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Raspberries are vibrant, juicy, and somewhat tart berries known for their rich fiber and antioxidant content. The berries are plucked and enjoyed as a healthy snack or topping on oatmeal and yogurt. But did you know that the leaves of the raspberry plant ( Rubus idaeus ) may have health benefits, too? You may have heard of red raspberry leaf tea. It is a caffeine-free herbal tea made from the dried leaves of the fruit-bearing plant.
When Ted Matthews came out of retirement in early 2023 to retake the helm of the rural Texas hospital where he’d started his health care career, it was something of a rescue mission. They were having bake sales to keep the place afloat. Staff were updating their resumes. At every board meeting, they’d decide which bills to pay. “It was the consensus that we were going to be that twenty-seventh rural hospital in Texas to close,” said Matthews, interim CEO of Anso
The United States leads the world in the research, development and manufacturing of innovative medicines. But the Inflation Reduction Act’s (IRA) “pill penalty” puts this leadership at risk by discouraging the development of treatments that often come in pill form like a tablet or capsule, also known as small molecule medicines. Under the IRA, these treatments can be price set years before other medicines, signaling to researchers that developing them is not worth the risk.
The study aims to address lingering public concerns, but its findings and communication have the potential to impact vaccine confidence and public health efforts.
The top reported barriers to providing buprenorphine included regulatory and administrative, operational and attitudinal, and patient-related challenges.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
TriCare, the federal health insurer for the military, has temporarily stopped paying the medical claims of pain management device maker Zynex Medical. In a recent filing with the Securities and Exchange Commission, Zynex revealed that the government payer — which represents up to a quarter of Zynex’s annual revenue — was suspending payments as it reviewed prior claims.
Panelists discuss how antibody-drug conjugates (ADCs) often show more diverse outcomes in real-world settings compared with clinical trials, with varying efficacy and adverse effect profiles. Key practical considerations for pharmacists include appropriate dosing based on patient factors, managing drug interactions, implementing premedication protocols to minimize adverse reactions, and providing comprehensive supportive care.
Elizabeth Pogge, PharmD, professor in the College of Pharmacy at Midwestern University, discusses initiating anticoagulation for older adults as well as the risk-benefit balance of the therapy.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
NEW YORK — To gene therapy pioneer Jim Wilson, the field is currently clouded with “irrational pessimism.” Companies are abandoning ship; approved therapies aren’t being prescribed. Yet both he and University of Pennsylvania researcher Kiran Musunuru are forging ahead, using contrasting approaches, as they explained onstage at STAT’s Breakthrough Summit East.
Introduction Social media has become an essential tool for pharmaceutical marketing. However, simply posting content is not enough. To measure success and improve engagement, pharma marketing teams must focus on the right social media analytics. But which metrics truly matter? With increasing regulations, evolving digital trends, and shifting audience behaviors, pharma marketers need to analyze data that aligns with brand goals, compliance requirements, and engagement strategies.
Among the drugs presented, Biktarvy and lenacapavir, teropavimab, and zinlirvimab (LTZ) demonstrate rates of suppression of HIV, and vesatolimod is well tolerated.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Three years ago, Arbor Biotechnologies CEO Devyn Smith appeared at the J.P. Morgan Healthcare Conference and laid out a grand vision: With $215 million in new capital, the biotech would push forward CRISPR-based drugs for a series of liver and brain diseases, beginning by filing for a first trial in under two years. It was, suffice to say, bold.
Introduction In todays competitive pharmaceutical landscape, marketing strategies must evolve to meet changing customer expectations. Are you still relying on traditional marketing tactics, or have you embraced a more dynamic, omnichannel marketing approach? With healthcare providers (HCPs) and patients engaging across multiple digital and offline touchpoints, pharma brands that fail to adapt risk losing valuable market share.
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning! There’s sure to be a lot of news coming out of the Breakthrough Summit East today, which is taking place just a few blocks away from my favorite Shake Shack in Manhattan. In-person tickets are sold out, but you can still snag a virtual ticket here.
Introduction In the highly regulated pharmaceutical industry, audience engagement is more than just a marketing goalit is a necessity for building trust with healthcare professionals (HCPs) and patients. But how can pharma brands create meaningful connections in a digital landscape crowded with content? Unlike traditional consumer marketing, pharma marketing requires a strategic approach that balances compliance, education, and innovation.
By Sara W. Koblitz Integral to the careful balance Congress struck when passing the Hatch-Waxman Amendments, the patent term extension (PTE) is intended to restore patent life that was consumed during regulatory review of an FDA-regulated product. Even though the PTE provisions established in the Drug Price Competition and Patent Restoration Act are forty-plus years old, courts are still grappling with questions about how to best implement the Patent Term Extension.
Top of the morning to you, and a fine one it is, despite the dreary gray skies hovering over the Pharmalot campus. We are doing our best to maintain sunny spirits, though, because once again, we recall some helpful wisdom from the Morning Mayor, who taught us that “every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and inviting you to join us.
Introduction The healthcare industry is undergoing a significant transformation, and ad budgeting is at the center of this shift. With the rapid expansion of digital platforms, evolving patient expectations, and the increasing role of AI-driven marketing, pharmaceutical companies and healthcare brands are allocating more resources to advertising in 2025.
In an Axios analysis of US Senate lobbying disclosures from the past year, researchers explored the ongoing trends of how certain industries distribute influence among legislators.
As a reformed hypochondriac, I’m extremely vulnerable to the allure of pharmaceutical ads. I self-referred for GLP-1s years ago after seeing advertisements, and even though I am a diabetic, what followed were horrific health outcomes: hospitalizations, extensive procedures, scans, MRIs, pancreatitis, anemia, and thousands in medical expenses.
Novo Nordisk has regained full membership with the Association of the British Pharmaceutical Industry (ABPI), following suspension in 2023. This action resulted after the pharmaceutical company made serious breaches of the ABPI Code of Practice in 2021. The case was the eighth instance in the past four decades that the ABPIs board has issued this degree of sanction, the industry body highlighted upon announcing the news.
In an era of rapid healthcare evolution, clinical pharmacy is at a crossroads in Europe, facing both unprecedented opportunities and pressing challenges, and Dr Monika Lutters, ESCP president, is at the forefront of these developments. Here, speaking to Gerry Hughes, she shares her insights on current clinical pharmacy challenges around expansion and integration of hospital pharmacists, and the exciting trajectory this branch of pharmacy is set to undertake in the years ahead.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
52 
Let's personalize your content